dm+d
10049011000001109
Articles
MSATS – Safe use of valproate
28 February 2024
Treating bipolar disorder during breastfeeding
5 October 2023
Specific medicine switches for solid dose and liquid formulations
13 September 2023
Valproic acid and Sodium valproate monitoring
15 July 2021
The Use of Generic Anti Epileptics Drugs in Patients with Epilepsy
28 September 2020Consensus views of the Pharmaceutical Market Support Group and the UK Clinical Pharmacists Association: Neurosciences Group on the safety and appropriateness of switching between brand…
Medicine Compliance Aid Stability
EpilimSanofi
Sanofi
Epilim
Tablets crushable 100mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Company info - if benefit outweighs risk, repackage weekly not monthly and protect from moisture and humidity.
2 March 2015
EpisentaDesitin
Desitin
Episenta
Capsules m/r 150mg, 300mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Unsuitable for MCA as preparations are hygroscopic which can affect release profile.
25 October 2022
genericNon-proprietary
Non-proprietary
generic
Tablets e/c 200mg, 500mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Unsuitable for MCA as preparations are hygroscopic which can affect release profile.
25 October 2022
Epilim ChronoSanofi
Sanofi
Epilim Chrono
Tablets m/r 200mg, 300mg, 500mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Company info - if benefit outweighs risk, repackage weekly not monthly and protect from moisture and humidity.
2 March 2015
EpilimSanofi-Aventis
Sanofi-Aventis
Epilim
Tablets e/c 200mg, 500mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Unsuitable
Company info - if benefit outweighs risk, repackage weekly not monthly and protect from moisture and humidity.
2 March 2015
Lactation Safety Information
For bipolar disorder
For bipolar disorder
Carbamazepine; Appropriate second generation antipsychotic
Significant published evidence of safety in breastfeeding indicates small amounts in breast milk
Monitor infant for jaundice, bruising, and bleeding
MHRA states that it should not used in women of child bearing age unless Pregnancy Prevention Programme is in place, and only if other treatments are ineffective or not tolerated. For this reason, carbamazepine is preferred first-line in breastfeeding (see summary)
26 July 2021
Oral / parenteral for epilepsy
Oral / parenteral
for epilepsy
Suitable alternative antiepileptic
Significant published evidence of safety in breastfeeding indicates small amounts in breast milk
Monitor infant for jaundice, bruising, and bleeding
Used in full-term neonates from birth
MHRA states that it should not used in women of child bearing age unless Pregnancy Prevention Programme is in place, and only if other treatments are ineffective or not tolerated (see summary).
26 July 2021